Skip to main content

Canadian vaccine yields promising early results

Share
TORONTO -

The University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) has announced positive early results from phase one trials of its COVID-19 vaccine candidate: COVAC-2.

The results from the study show that the vaccine appears to be safe and “well tolerated,” according to a press release.

The study, conducted by Canadian Centre for Vaccinology (CCfV), said that the most commonly reported side effects among those who received the vaccine were headaches and mild pain at the injection site.

The study found that, even with low doses of the vaccine, there was enough of an antibody response to provide protection against COVID-19, according to the press release.

“The data continues to demonstrate the safety of our subunit vaccine COVAC-2. We are encouraged by the vaccine’s ability to generate a significant immune response, even at the lowest dose tested,” Dr. Volker Gerdts, director and CEO of VIDO, said in the release.

The COVAC-2 vaccine is a subunit vaccine, meaning it contains “purified viral proteins” that are not infectious.

CTVNews.ca Top Stories

Mussolini's wartime bunker opens to the public in Rome

After its last closure in 2021, it has now reopened for guided tours of the air raid shelter and the bunker. The complex now includes a multimedia exhibition about Rome during World War II, air raid systems for civilians, and the series of 51 Allied bombings that pummeled the city between July 1943 and May 1944.

Local Spotlight

Stay Connected